에피제네틱스 진단 시장 규모, 점유율, 동향 분석 : 제품별, 기술별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Epigenetics Diagnostics Market Growth & Trends:

The global epigenetics diagnostics market is anticipated to reach USD 39.15 billion by 2030 and is anticipated to expand at a CAGR of 15.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to increased investment, funding, and approvals for epigenetics research and development, and the increasing prevalence of MDD (Major Depressive Disorder). According to the World Health Organization (WHO), in 2023, approximately 5% of adults experienced depressive disorders. Furthermore, a study published by the National Center for Biotechnology Information (NCBI) in 2022 reported that around 280 million people worldwide are affected by MDD. Epigenetics' applications in drug discovery and development are growing, and genome sequencing is becoming more affordable. Additionally, advancements in technology related to epigenetic drug discovery contribute to this growth.

Additionally, an increase in investment from both public and private organizations in epigenetics is expected to drive market growth from 2023 to 2030. In February 2025, TruDiagnostic introduced the grant, which provides USD 400,000 in funding to support researchers working in DNA methylation, longevity science, and diagnostic innovation. A study published by NCBI in 2022 stated that epigenetic modification plays a crucial role in maintaining cellular homeostasis and the genome and provides information about the cause and development of virus infection.

Epigenetics Diagnostics Market Report Highlights:

• Reagents dominated the product segment with more than 30.0% share in 2024, owing to their high usage in epigenetic research studies.
• The DNA Methylation segment is expected to grow at the fastest CAGR of 44.5% over the forecast period 2025 - 2030.
• The oncology segment held the largest market share in 2024, and with the increasing incidence of cancer, the epigenetic market is expected to grow over the forecast period.
• The academic research segment held the largest market share in 2024. The growth is attributed to the factors such as increased funding for research and development by various companies and supportive initiatives from the government.
• North America led the epigenetic diagnostics market in 2024 due to the presence of key market players and an advanced healthcare infrastructure. Additionally, increasing awareness along with significant R&D expenditure is expected to fuel growth throughout the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Technology
  • 1.2.3. Application
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product
  • 2.2.2. Technology
  • 2.2.3. Application
  • 2.2.4. End Use
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Epigenetics Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Epigenetics Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Epigenetics Diagnostics Market: Pipeline Analysis

Chapter 4. Epigenetics Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Epigenetics Diagnostics Market: Product Movement Analysis
• 4.3. Global Epigenetics Diagnostics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Reagents
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Kits
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. ChIP Sequencing Kit
    • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Whole Genomic Amplification kit
    • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Bisulfite Conversion kit
    • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.5. RNA Sequencing kit
    • 4.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.6. Others
    • 4.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million
• 4.6. Instruments
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Enzymes
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Services
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Epigenetics Diagnostics Market: Technology Estimates & Trend Analysis

• 5.1. Technology Segment Dashboard
• 5.2. Epigenetics Diagnostics Market: Technology Movement Analysis
• 5.3. Epigenetics Diagnostics Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 5.4. DNA Methylation
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Reagents
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Kits
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Instruments
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Enzymes
    • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.6. Services
    • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Histone Methylation
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. Reagents
    • 5.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.3. Kits
    • 5.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.4. Instruments
    • 5.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.5. Enzymes
    • 5.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.6. Services
    • 5.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Histone Acetylation
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Reagents
    • 5.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.3. Kits
    • 5.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.4. Instruments
    • 5.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.5. Enzymes
    • 5.6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.6. Services
    • 5.6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Large non - coding RNA
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.2. Reagents
    • 5.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.3. Kits
    • 5.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.4. Instruments
    • 5.7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.5. Enzymes
    • 5.7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.6. Services
    • 5.7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. MicroRNA modification
  • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.2. Reagents
    • 5.8.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.3. Kits
    • 5.8.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.4. Instruments
    • 5.8.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.5. Enzymes
    • 5.8.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.6. Services
    • 5.8.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Chromatin structure
  • 5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.2. Reagents
    • 5.9.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.3. Kits
    • 5.9.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.4. Instruments
    • 5.9.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.5. Enzymes
    • 5.9.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.6. Services
    • 5.9.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Epigenetics Diagnostics Market: Application Estimates & Trend Analysis

• 6.1. Application Segment Dashboard
• 6.2. Epigenetics Diagnostics Market: Application Movement Analysis
• 6.3. Global Epigenetics Diagnostics Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Solid tumors
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Liquid tumors
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Non - Oncology
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Inflammatory diseases
    • 6.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Metabolic diseases
    • 6.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Infectious diseases
    • 6.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Cardiovascular diseases
    • 6.5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Others
    • 6.5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Epigenetics Diagnostics Market: End Use Estimates & Trend Analysis

• 7.1. Application Segment Dashboard
• 7.2. Epigenetics Diagnostics Market: End Use Movement Analysis
• 7.3. Global Epigenetics Diagnostics Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Academic Research
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Clinical Research
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Hospitals & Clinics
  • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Pharmaceutical & Biotechnology Companies
  • 7.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Other Users
  • 7.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Epigenetics Diagnostics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2024 & 2030
• 8.3. Continuous bioprocessing market by Region: Key Takeaways
• 8.4. North America
  • 8.4.1. U.S.
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Canada
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. Mexico
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. UK
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. Germany
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. France
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Italy
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. Spain
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Denmark
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.7. Sweden
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework/ reimbursement structure
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.8. Norway
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Regulatory framework/ reimbursement structure
    • 8.5.8.3. Competitive scenario
    • 8.5.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Japan
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. India
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. Australia
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Thailand
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Brazil
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Argentina
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. South Africa
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.2. Saudi Arabia
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. UAE
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework/ reimbursement structure
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.4. Kuwait
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Regulatory framework/ reimbursement structure
    • 8.8.4.3. Competitive scenario
    • 8.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. Key company heat map analysis, 2024
• 9.4. Company Profiles
  • 9.4.1. Hoffmann- La Roche Ltd.
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Thermo Fisher Scientific, Inc.
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Eisai Co. Ltd.
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Novartis AG
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Element Bisosciences, Inc.
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Cantata Bio (Dovetail Genomics LLC.)
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Illumina, Inc.
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. ValiRx Plc.
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Abcam Ltd.
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives